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Glioblastoma Multiforme GBM is a very aggressive type of malignant brain tumors 
that affects ??????????????? The diffusive, infiltrative, and metastatic behaviour of GBM is 
the major reason for the disease recurrence. The morphological and immunohistological 
characteristics of Central Nervous System (CNS) tumors including GBM are 
heterogeneous. GBM is either primary (de novo) or secondary to low-grade 
astrocytomas.  
Current treatment options include surgery, radiotherapy, and temozolomide 
chemotherapy have not achieved any improvement in success rates over the past decades. 
The survival time reached by GBM patients was approximately 12 months only after 
being treated with radiotherapy alone without temozolomide. However, the median 
survival time has been estimated as 14.6 months in patients who received the combined 
treatment of radiotherapy and chemotherapy with temozolomide. Temozolomide is an 
alkylating agent that exhibit antitumor activity and prescribed as a single agent for the 
treatment of recurrent glioma. It diminishes the O6-methylguanine-DNA 




Patientswith activated O6-alkylguanine transferase AGT enzyme were reported to 
develop resistant to temozolomide. 




Targeting the immune system will identify successful treatments for GBM with 
significant clinical benefits. The use of active immunotherapy to increase the native 
immune response or passive immunotherapy to target the tumor cells in GBM patients 
are under investigation. Dendritic Cells DCs are the most potent antigen presenting APCs 
in the immune system. DCs have the ability to stimulate the native T cells and induce 
primary immune responses and peripheral immunological tolerance through capturing, 
processing neoantigens, which are formed and released by oncogenesis, and presenting 
the captured antigens on Histocompatibility Complex I and II (MHCI and MHCII) 
molecules to T cells. After that T cell responses against the cancer-specific antigens are 
primed and activated. T cells infiltrate the tumor bed, specifically recognize, bind to, and 
kill their target cancer cell. The sources of antigen that have been used in DC 
immunotherapy include exogenous MHC-restricted peptides, acid-eluted tumor peptides, 
tumor RNA and cDNA, viral vectors, apoptotic tumor cells, tumor cell lysate, and whole 
glioma cells. Clinical trials showed that treating GBM patients with surgery, TMZ, and 
Dendritic Cell DC vaccines was safe and achieved meaningful clinical outcomes. 
The purpose of this research is to investigate the clinical outcomes of DC vaccines 




of clinical trials. Furthermore, this research focuses on investigating immune responses 
that are related to the most beneficial clinical outcomes to identify new prognostic 
biomarkers and therapeutic targets. 
????????????????findings have showed evidence that many different variables were 
associated with different cancer specific immune responses and clinical outcomes. These 
variables include loading DC vaccines with tumor material or Tumor Associated 
Antigens TAAs, and combining DC vaccines with different pre and post vaccination 
treatment strategies.  DC vaccine pulsed with specific synthetic antigens have achieved 
more beneficial clinical outcome than DC vaccines loaded with tumor material. Pre-
vaccination treatment strategy with TMZ has increased the Overall Survival and the 
Progression Free Survival of GBM patients. Although, pre-vaccination treatment strategy 
with TMZ+RT has achieved significant improvement of Overall Survival, there was no 







CHAPTER 1. INTRODUCTION 
This chapter introduces the overview of Glioblastoma Multiforme (GBM) research 
work. This chapter provides a statement of the problem in GBM cancer studies, research 
question, scope, significance, definitions of key terms, assumptions, limitations, and 
delimitations of this research study. 
 
1.1 Statement of the Problem  
Glioblastoma Multiforme GBM is a very aggressive type of malignant brain tumors 
??????????????????????????????????????????????????????????????????????????????????????
and causes major mutations in cell signaling and growth. Current treatment options 
including surgery, radiotherapy, and temozolomide chemotherapy have not achieved any 
improvement in success rates over the past decades. Targeting the immune system will 
identify successful treatments for GBM with significant clinical benefits. The purpose of 
this research is to investigate innovative immunotherapies for GBM by using data 
published on the rapidly growing field of clinical trials. 
 
1.2 Research Question  
Do innovative immunotherapies for Glioblastoma Multiforme have the ability to 





The scope of this research is to investigate the innovative immunotherapies for the 
treatment of Glioblastoma Multiforme (GBM) using available published literature and 
various data analysis techniques. This study is conducted to explore the clinical outcomes 
of Dendritic Cell vaccines; which are currently under investigation for the treatment of 
GBM. The study is exploring the efficiency of the treatment combination of 
immunotherapy, chemotherapy, following surgical resection of the tumor mass. 
Furthermore, the study focuses on identifying immune responses, prognostic biomarkers, 
and new therapeutic targets for GBM. 
 
1.4 Significance  
The treatment options of Glioblastoma Multiforme, including surgical removal, 
radiation therapy, and cytotoxic chemotherapy, are very aggressive as well as they do not 
achieve any improvement in the disease state. This research will use data published on 
the rapidly growing field of clinical trials to provide in depth knowledge about GBM and 
host factors that are related to immune system interactions. 
The research investigates innovative immunotherapies, which present a potential 
solution to treat Glioblastoma Multiforme. The result of this work will be a seed for 
future research on identifying a new treatment with significant clinical benefits that is 





1.5 Definitions of Key Terms  
Apoptosis is a genetically encoded cell death program which is well known by the 
corresponding morphologic and biochemical changes (Fisher, 1994). 
Biomarkers are measureable quantities of biologic homeostasis that are used to 
differentiate between normal and abnormal and can be detected using recent 
technological advances (Dalton & Friend, 2006). 
Brain metastases are brain tumors that originate in specific tissue of origin outside the 
brain and metastasize to the brain which resemble more than 50% of all brain 
tumors in adults (Jacobs et al., 2009). 
Carcinogen is a chemical, physical or viral stimuli which directly induces cancer by 
formation of DNA adducts and initiation of various genetic mutations 
(Higginson, 1987; Herbst, Heymach, & Lippman, 2008). 
CD25+ CD4+ are suppressor Tregs lymphocytes which make the immunity system 
unresponsive to self-constituents, establish what is known as self-tolerance, and 
maintain a negative control of pathological and physiological immune responses. 
(Sakaguchi, 2004).  
Dendritic cells (DCs) are antigen-presenting cells, which act by capturing and 
transferring information from the surrounding environment to the cells of the 
adaptive immune system. They can induce primary immune responses, 
immunological  tolerance, and regulate T cell?mediated immune response 




Immune system is the body system, which recognize foreign invaders and eliminate 
them. It has the ability to distinguish between self- and non-self-constituents (or 
antigens) (Thomas, Ernstoff, & Fadul, 2012). The immune system includes two 
major branches: the innate and the adaptive immune systems (Kanaly, Ding, 
Heimberger, & Sampson, 2010).   
Oncogene is mutated gene which is resulted from different carcinogens and causes 
intensive cell growth that proliferates into cancer cells (Herbst et al., 2008). 
Temozolomide (TMZ) is DNA alkylating agent which exhibits antitumor activity and is 
used for the treatment of Glioblastoma Multiforme (Stupp et al., 2005). 
 
1.6 Assumptions 
The assumptions of this thesis will include: 
? The sources of data are trusted. 
? Data analysis will be accurate and no data will be missed. 
 
1.7 Limitations 
The following limitations are inherent to the pursuit of this study:  
? The research will investigate the innovative dendritic cell vaccines for the 









? This study will not investigate the efficacy of the chemotherapy or the 
radiotherapy treatments. 
? This study will not investigate the adaptive immunotherapies. 
1.9 Summary 
This chapter has provided an overview of the research study, including statement of 
purpose, research question, scope, and significance, definitions of key terms, 




CHAPTER 2. LITERATURE REVIEW  
This chapter presents an overview of Glioblastoma Multiforme (GBM), 
Epidemiology, Metastases, cancer stem cell hypothesis, treatment options ?Radiotherapy, 
???????????, and ?????????????, immune reactions in healthy brain and in 
Glioblastoma patients, immunotherapy for the treatment of GBM, adoptive 
immunotherapy, active immunotherapy, and nanotechnology in immunotherapy for the 
treatment of GBM. It also introduces DC development, diversification, maturation, and 
function, tumor associated antigens TAA, and end points and evidences of therapeutic 
activity. 
 
2.1 Glioblastoma Multiforme 
Glioblastoma Multiforme (GBM) is a brain tumor with severe manifestations of 
anaplasia and dedifferentiation of glia, which is representing about 50 % of all gliomas. 
Glioblastoma is the most aggressive, complex, and common human brain tumor type, 
which is known as grade four gliomas (Holland, 2000). Morphological and 
immunological features show that the proliferation of Glioblastoma is accompanied by 
immunological reaction against tumor-specific antibodies. It is the most malignant 
primary intracranial neoplasm, which is identified by a gross and microscopic 




ages under 40 years, although the peak age incidence lies between 48 and 55 years 
(Jellinger, 1978).  
  CNS tumors such as Glioblastoma Multiforme are caused by genetic mutation 
that results in a progressive neoplastic transformation of differentiated cells (Jellinger, 
1978). The genetic mutation is characterized by several deletions, amplifications, and 
point mutations that is followed by activation of signal transduction pathways, inhibition 
of tyrosine kinase receptors, and disturbance in cell-cycle arrest pathways either by 
INK4a-ARF gene loss or tumor suppressor p53 gene mutations (Holland, 2000). 
 
2.2 Epidemiology 
Central nervous system (CNS) primary tumors are affecting approximately 18.71 
per 100,000 persons per year (States & others, 2010). Primary brain tumors are the main 
cause of deaths in cancer patients and it represents about 2.3 % of deaths in cancer 
????????????????????????????????????????????????????????????????????????????????????
2010).  
Glioma is the most common primary brain tumor with the incidence percent of 32 
% of CNS tumors and 80 % of malignant CNS tumors as shown in Figure. 2.1 (Agnihotri 
et al., 2013). 
Glioblastomas are the most malignant glioma and the main type of astrocytoma 
with an incidence percent of about 54 % of the astrocytic tumors. The incidence ratio of 
Glioblastomas is 1.58:1 in men and women and 2:1 in Caucasians and African-
Americans respectively (States & others, 2010). Malignant gliomas are thought to be 




syndrome such as neurofibromatosis types 1 and 2, and Li-Fraumeni syndrome (Farrell & 
Plotkin, 2007). 
2.3 Metastases 
Metastasis is an invasive property that arises from interactions between cancer 
cells and their microenvironment. This action is mostly due to the loss of the cell-cell 
adhesion that is controlled by E-cadherin. The inactivation of E-cadherin originates from 
inactive protein, gene silencing or the overexpression of the growth factor receptors. 
There are also a number of genes which are responsible for genetic and epigenetic 
mutations in cancer cells and are supported by micro environmental changes to initiate 
metastatic behaviour of tumors (Chiang & Massagué, 2008). These genes are divided into 
three groups: initiation, progression, and virulence genes (Nguyen & Massagué, 2007). 
Genes that are responsible for the progression of metastasis make the cancer cell capable 
of traveling successfully between different points until it reaches the distant site that is 
identified by those genes. Genes that cause metastatic initiation are operating in the 
primary tumor site and the distant metastatic site. This classification of the genes that are 
responsible for cancer metastasis and their functions is important to provide a 
multidimensional explanation of metastasis and is crucial to establish several anti-





Figure 2.1 Primary brain tumor epidemiology. A shows the percent distribution of all a 
primary brain and CNS by histology. B shows the percent of primary brain gliomas in the 
United States (2004-2006) (Agnihotri et al., 2013). 
 
Glioblastomas or grade four gliomas are more proliferative, infiltrative, and 
invasive in nature than grade one, two, and three astrocytoma (Kleihues & Sobin, 2000).  
This diffusive and infiltrative nature of glioblastoma is the major reason for the surgical 
incurability and disease recurrence. The malignant cells of Glioblastoma disseminate 
from the primary tumor site and migrate in specific routes that depend on the structure of 
the brain and the connected extra cellular matrix (Agnihotri et al., 2013). Glioblastomas 
migrate commonly through dispersing in the tracks of the white matter, the basal lamina 
of the brain blood vessels, or in between the glia limitans and the pia mater (Bellail, 




2.4 Cancer Stem Cell Hypothesis 
The original cell of GBM that is predicted to develop neoplastic lesions to initiate 
cancer follows three possible assumptions. The first assumption is the ability of a 
dedifferentiated mature glia to develop abnormal stem-cell like properties through 
epigenetic lesions that is initiated by mutation. The second assumption is that restricted 
neural progenitors with a limited self-renewal property can develop mutations and also 
gain stem-cell like properties. The third assumption is that adult neural stem cells 
(NSCs), which are normally proliferate and differentiate is capable of developing 
mutations and tumor formation (Dirks, 2008; Dirks, 2001; Stiles & Rowitch, 2008).  
Glioblastoma arises from cells that are able to obtain stem-cell like properties, grow 
abnormally, and initiate tumor formation. This concept is the base of the cancer stem cell 
hypothesis, which is shown in Figure 2.2 (Agnihotri et al., 2013). Normal cells of the 
central nervous system differentiate and central nervous system tumor is initiated. Neural 
stem cells are forming neural and glial progenitors, which differentiate into the principle 
cell types of the central nervous system neurons, oligodendrocytes and astrocytes. Tumor 
initiating cells (BTICs) are thought to come from terminally differentiated cells as shown 








Figure 2.2 The original cells of Glioblastoma Multiforme (Agnihotri et al., 2013). 
 
Central nervous system (CNS) tumors are classified based on their morphological 
and immunohistological characteristics which outline the predominant cell type. GBM 
can be classified into two main subgroups with different genetic pathways. Primary or de 
novo GBM occurs mostly in older patients with no in advance occurrence of low-grade 
astrosytomas. However, secondary GBM occurs in young patients and originates from 







Figure 2.3 GBM subtypes with different genetic pathways (Endersby & Baker, 2008) 
 
2.5 Treatment Options for Glioblastoma Multiforme 
   The current standard of treatment options of Glioblastoma have not changed over 
the last decades. The first line of treatment is the surgical resection of the tumor, followed 
by radiotherapy.  In the United States, a nitrosourea drug (carmustine) is usually 
recommended ; (Walker, Laherty, Tomlinson, Chuah, & Schmidt, 2008). 
           Complete surgical resection of tumor mass is impossible due to the 
topographically diffusive nature of the disease and the large location variability of the 
tumor cells within the brain. This behavior results in the diffusion of the tumor cells 
within large distances, particularly into the brain vital regions that ????????????????????????s 
survival. Recurrence of the tumor can occur at the surgical margin and other sites after a 






          Radiotherapy and chemotherapy are following the surgical resection of the tumor 
and achieve an expected mean survival that lies between two months and one year 
(Jelsma & Bucy, 1967).  There is a great improvement in survival time resulting from the 
combination treatment of radiotherapy and chemotherapy using temozolomide with a 
median survival time of 14.6 months (Dieckmann, 2010). Modern radiotherapy aims to 
increase the dose that is delivered to the tumor region, decrease the dose that is delivered 
to the normal brain tissue, and avoid local necrosis (Stupp et al., 2005). The combined 
treatment of radiotherapy and chemotherapy with temozolomide in Glioblastoma has 
achieved a median survival of 14.6 months; however, the survival time was 12 months 
only without temozolomide. The image-based conformal radiotherapy achieved two 
years, which is considered crucial before and after surgical resection (Stupp, 2006; Stupp 
et al., 2002).  
              The standard technique of radiotherapy is based on three-dimensional conformal 
processes that depend on magnetic resonance imaging and x-ray computed tomography 
fused data sets. There is an optimal advantage over the use of these data sets in the pre-
operative and the post-operative stages. The pre-operative gross tumour volume 
measurement achieves a significant advantage in the postoperative structures evaluation. 
Follow-up is necessary in order to increase the efficiency of the radiotherapy techniques 









?????????????????????????(Cohen, Shen, Keegan, & Pazdur, 2009)?????????????????????
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?????????????????????????????(Bender et al., 2008)?  There were a major differences ???
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             Temozolomide is an alkylating agent that is prescribed as a single agent for the 
treatment of recurrent glioma. The drug is administered orally and exhibit antitumor 
activity (Newlands, Stevens, Wedge, Wheelhouse, & Brock, 1997;  W. K. A. Yung et al., 
2000).The dosing regimen consists of 150 to 200 mg for the square meter of body-surface 
area to be administered once daily for 5 days of every 28-day cycle (Stupp et al., 2005). 
Another dosing regimen consists of 75 mg for the square meter to be administered once 
daily during seven weeks (Brock et al., 1998). Temozolomide diminishes the O6-
methylguanine-DNA methyltransferase (MGMT) enzyme which is responsible for the 
repair of the DNA (Tolcher et al., 2003). The decrease in the O6-methylguanine-DNA 
methyltransferase enzyme in tumor site is found to increase the survival of the 
Glioblastoma patients who are receiving nitrosourea-based adjuvant chemotherapy 
(Esteller et al., 2000; Hegi et al., 2004). 
Temozolomide is a prodrug with a small size (194 Da) which is optimally 
absorbed in the small intestine and penetrate the blood-brain barrier. It undergoes 
spontaneous hydrolysis in the cells and converts to a strong methylating agent MTIC. 




formed and apoptosis occur as a result of the failure of the cellular repair mechanisms to 
repair the methylated base  (Wesolowski, Rajdev, & Mukherji, 2010). 
A randomized phase III trial showed that temozolomide had increased the median 
survival and achieved a 2-year survival time after the drug was added to the standard 
postoperative radiotherapy. 573 patients from 85 institutions in 15 countries were 
randomly enrolled in the trial including 286 patients have received radiotherapy alone 
and 287 patients have received temozolomide combined with radiotherapy. Longer 
survival was observed in patients (with a methylated and un-methylated MGMT 
promoter) who have received the combined therapy of temozolomide and radiotherapy 
than in patients who have received radiotherapy alone (Stupp et al., 2009).  
There are other three meaningful studies involved patients with malignant glioma 
who have received previous treatment but encountered disease progression. One major 
study had investigated the effects of Temodal in 138 patients with Glioblastoma 
Multiforme. Another study compared Temodal with procarbazine in 225 GBM patients. 
The final study investigated the safety and effectiveness of Temodal in the treatment of 
162 patients with anaplastic astrocytoma who were in their first relapse. Effectiveness 
???????????????????????????????????????????????????????????????????????????????????????????
to start getting worth. The average survival time in GBM Patients was 14.6 months when 
they received Temodal and radiotherapy, compared with 12.1 months with radiotherapy 
alone.  
The biological activity of TEMODAR in pediatric patients has not been 
identified. Phase II studies on TEMODAR Capsules have been conducted in pediatric 




days. A clinical trial was conducted by the Schering Corporation in which 29 patients 
with recurrent brain stem glioma and 34 patients with recurrent high grade astrocytoma 
????????????????????????????????????????????????????????????????????????????????
Oncology Group (COG) in which 122 patients were enrolled. The clinical trials showed 
the same toxicity profile for TEMODAR in pediatric and adult patients (FDA 
TEMODAR® (temozolomide) capsules, 2006). 
 Resistance to temozolomide is mediated by the enzyme O6-alkylguanine 
transferase AGT(Stupp, Gander, Leyvraz, & Newlands, 2001). GBM Patients who have 
inactivated AGT (methylated promoter) achieve more clinical benefits from TMZ than 
patients with activated AGT (non-methylated promoter) (Esteller et al., 2000). 
Standard carcinogenicity and reproductive function studies were not conducted 
with temozolomide. Mammary carcinomas were observed in both male and female rats 
after they were treated with 200 mg/m2 temozolomide on 5 days every 28 days for 3 
cycles. Mammary carcinomas and fibrosarcomas of different body organs were observed 
after 6 cycles of receiving temozolomide at 25, 50, and 125 mg/m2. In vitro mutagenicity 
was observed in bacteria (Ames assay). Clastogenicity in mammalian cells was observed 
(human peripheral blood lymphocyte assays). Multicycle toxicology studies in rats and 
dogs have indicated testicular toxicity (syncytial cells/immature sperm, testicular 
atrophy) at doses of 50 mg/m2 in rats and 125 mg/m2 in dogs (FDA TEMODAR® 
(temozolomide) capsules, 2006). 
Temozolomide received an accelerated approval by the U.S. Food and Drug 
Administration in January 1999 for the treatment of anaplastic astrocytoma patients who 




drug received full approval after the clinical benefits for temozolomide and radiotherapy 
were compared with radiotherapy alone.  On March 15, 2005, the FDA approved 
temozolomide combined with radiotherapy for the treatment of Glioblastoma Multiforme 
(Cohen, Johnson, & Pazdur, 2005). The European Committee for Medicinal Products for 
???????????????????????????????????????????????????????????????????????????????
received approval for the treatment of Glioblastoma Multiforme from The (CHMP) on 26 
January 1999. 
 
2.9 Immune Reactions in Healthy Brain 
The Blood Brain Barrier BBB is a unique, selective barrier which consists of the 
endothelial cells and perivascular elements such as closely associated astrocytic end-feet, 
perivascular neurons and pericytes as shown in figure 2.4 (a). Several membrane 
transporters are present in the brain endothelial cells. They are responsible for the 
regulation of the penetration of essential molecules from the blood circulation into the 
brain. Membrane transporters are also responsible for the effluxing of potentially harmful 
substances and waste products out of the brain cells. P-glycoprotein (P-gp) and the 
multidrug resistance-associated protein family are the most important efflux transport 
systems responsible for drug delivery to the CNS. The presence of complex tight 
junctions (TJ) and adherens junctions (AJ) makes the cerebral endothelial cells very 
unique. TJs prevent the penetration of polar molecules into the brain, however AJs 
stabilize cell?cell interactions in the junctional zone. In addition, there are intracellular 
?????????????????????????????????? ?????????????????????????-glutamyl transpeptidase 




enzymes which provide the BBB with the metabolic activity as shown in figure 2.4 (b) 





Figure 2.4 The cells of the BBB (a) and the existing membrane transporters (b) 
(Cecchelli et al., 2007). 
  
 It was thought that immune reactions do not occur in the brain due to the specific 
nature of the blood brain barrier. The brain has specific characteristics such as the 
absence of conventional lymphatic vessels and decreased number of circulating T cells. It 
is recently known that the central nervous system communicates with the immune system 
by the means of two-way communication pathways. Recent models such as infectious or 
experimental autoimmune encephalomyelitis animal models provide information about 
the specific operations of the immune system in the brain (Vauleon, Avril, Collet, 




            A healthy brain contains several different immune cell populations. Microglial 
cells resemble 5% to 20% of cells in the central nervous system starting from the 
embryonic development. Microglial cells arise from hematopoietic cells and are 
considered as the first line of defense in the brain.  Macrophages and dendritic cells (DC) 
are present in perivascular zones, the choroid plexuses, and the meninges. Macrophages 
and dendritic cells arise from the monocytes which are circulating in the blood stream 
(Vauleon et al., 2010). 
 Microglial cells travel to the inflammatory zones. undergo activation, obtain 
phagocytic properties, and produce different types of cytokines and chemokines which 
synthesise other types of immune cells (Tambuyzer, Ponsaerts, & Nouwen, 2009). The T 
cells are being activated in the cervical nodes, resulting in increasing the levels of ?4/?7 
integrins. Animal models showed that antigen presenting cells (APC) travel from the 
brain parenchyma through the external capsule to enter the cervical nodes which is the 
same drainage system pathway in humans and rodents (Karman, Ling, Sandor, & Fabry, 
2004). 
  The blood brain barrier exhibits a selective penetration of immune cells from the 
blood circulation into the brain parenchyma due to the complex cellular structure of the 
brain capillaries such as; endothelial cells with tight junctions, pericytic cells, and 
astrocytic cells. The penetration of the activated T cells across the blood brain barrier is 




The process is also controlled by several molecular interactions involving adhesion 
??????????????????????????????????????????????????????????XCR3 (Mrass & Weninger, 
2006; Wilson, Weninger, & Hunter, 2010). 
2.10 Immune Reactions in GBM patients 
             It is obvious that the rules that regulate the penetration of the effector T cells 
across the tumour tissues and the normal state rule are different (Vauleon et al., 2010). 
The blood brain barrier in GBM patients has abnormal asymmetric capillary structure. 
The tight junctions between endothelial cells are inactivated and the blood brain barrier 
associated pericytes are decreased in number (Mrass & Weninger, 2006; Davies, 2002; 
Rascher et al., 2002). The travelling of lymphocytes was tracked with injections of CD4+ 
lymphocytes in a model of autoimmune encephalitis to target myelin proteins.  
CD4+ lymphocytes entered the subarachnoid spaces and travelled through the 
internal wall first then through the external walls of the vessels. When CD4+ lymphocytes 
identify any Antigen Presenting Cells APC such as macrophages or dendritic cells in the 
myelin antigens, they become reactivated, produce numerous cytokines, and enter the 
brain parenchyma (Bartholomäus et al., 2009). CD8+ lymphocytes are locally expanded 
depending on the brain environment. Glioma mouse model showed that CD8+ 
lymphocytes first enter the brain, then undergo proliferation and differentiation 
depending on IFN??and granzyme B expression (Vauleon et al., 2010). CD8+ T cells have 
the ability to retain into the brain due to the presence of ?E?7 integrins (Masson et al., 
2007). This increased level of ?E?7 integrins is thought to be resulting from the presence 




the ability to expand in the brain depending on the overexpression of the dendritic cells 
(Lauterbach, Zuniga, Truong, Oldstone, & McGavern, 2006). 
 
2.11 Immunotherapy for Glioblastoma Multiforme 
 The occurrence of effective anticancer immune response is initiated and 
maintained by a series of stepwise events called the cancer-immunity cycle as shown in 
figure 2.5. In step 1, neoantigens are formed and released by oncogenesis and captured 
and processed by dendritic cells (DCs). In step 2, DCs present the captured antigens on 
MHCI and MHCII molecules to T cells. T cell responses against the cancer-specific 
antigens are primed and activated in step 3. In steps 4, 5, 6, and 7, the activated effector T 
cells traffic to, infiltrate the tumor bed, specifically recognize, bind to, and kill their target 
cancer cell. The cancer-immunity cycle is iterative because the death of the cancer cell 
releases additional tumor-associated antigens which strengthen the previously explained 
immune response (D. S. Chen & Mellman, 2013). The Cancer-Immunity Cycle is limited 
in GBM patients because the tumor antigens may not be detected and DCs and T cells 
may not recognize antigens as foreign. Moreover, T cells may not properly home to 
tumors, or may be inhibited from infiltrating the tumor. The suppression of those effector 
cells by tumor microenvironment is another important factor that also may limit the 
Cancer-Immunity Cycle ( Motz & Coukos, 2013).  
 
 The presence of checkpoints and inhibitors in each step of the cancer-immunity 
cycle may negatively affect the production of the antitumor immune response. 




immunostat function that takes place in the tumor microenvironment and cause 
immunosuppression (Jarrod Predina et al., n.d. ; Wang et al., n.d. ). Each step of the 
Cancer-Immunity Cycle has stimulatory; which initiate and maintain immunity and 
inhibitory factors; which inhibit immunity and also prevent autoimmunity. For example, 
CTLA4 is an immune checkpoint protein; which works on step 3 to prevent the 
development and proliferation of t cells and hinder the desired active immune response. 
There are also immune rheostat (immunostat) factors, such as PD-L1; which acts on step 
7 and modulate active immune responses in the tumor bed. Stimulatory and inhibitory 
factors of Cancer-???????????????????????????????????????????????????????????????IL, 
interleukin; TNF, tumor necrosis factor; IFN, interferon; CDN, cyclic dinucleotide; ATP, 
adenosine triphosphate; HMGB1, high-mobility group protein B1; TLR, Toll-like 
receptor; HVEM, herpes virus entry mediator; GITR, glucocorticoid-induced TNFR 
family-related gene; CTLA4, cytotoxic T-lymphocyte antigen-4; PD-L1, programmed 
death-ligand 1; CXCL/CCL, chemokine motif ligands; LFA1, lymphocyte function-
associated antigen-1; ICAM1, intracellular adhesionmolecule1; VEGF, vascular 
endothelial growth factor ;IDO,indoleamine2,3-dioxygenase; TGF, transforming growth 
factor; BTLA,B-and T-lymphocyte attenuator; VISTA, V-domain Ig suppressor of T cell 
activation; LAG-3, lymphocyte-activation gene 3 protein; MIC, MHC class I 
polypeptide-related sequence protein; TIM-3, T cell immunoglobulin domain and mucin 
domain-3?. These factors arise from the intratumoral T regulatory cells, macrophages, 
and myeloid-derived suppressor cells. There are also specific immunogenic signals such 
as proinflammatory cytokines and factors released by dying tumor cells that are crucial 






Figure 2.5  The cancer-immunity cycle (D. S. Chen & Mellman, 2013). 
 






The use of immunotherapy for the treatment of brain tumors consists of two 
options. The first option is the use of active immunotherapy that aims to increase the 
native immune response in Glioblastoma patients. The second option is the use of passive 
immunotherapy to target the tumor cells. Passive immunotherapy consists of in vitro 
activated immune cells or specific molecules such as antibodies which can be injected 
directly (Vauleon et al., 2010). 
 
2.12 Adoptive Immunotherapy  
            The in vitro activated immune cells are either being directly injected into the 
tumor tissues or intravenously in GBM patients (Vauleon et al., 2010). Lymphocyte-
activated killer cells are used for the treatment of Glioblastoma patients (Jacobs, Wilson, 
Kornblith, & Grimm, 1986; Robert Owen Dillman et al., 2009).  There are several 
clinical trials that were conducted on a number of High Grade Glioma patients and based 
on the use of lymphocyte activated killer cells LAK (Vauleon et al., 2010). The toxic 
effects of LAK include neurological toxicity and brain edema (Barba, Saris, Holder, 
Rosenberg, & Oldfield, 1989). Radiological response criteria were used to evaluate the 
improvement after the treatment was received by patients. One hundred and eighteen GG 
patients were enrolled in some LAK cells clinical trials; five patients were reported with a 
complete response, 13 patients with a partial response, and six patients with stable 
disease (Vauleon et al., 2010). Vaccinated Glioblastoma patients achieved a longer 
median survival than the median survival of the control groups (Hayes et al., 1995; Hayes 




survival of a newly diagnosed GBM patients reached 20.5 months and one year for 75% 
of the patients (Robert Owen Dillman et al., 2009). 
               Cytotoxic T lymphocytes (CTL) are also used for the treatment of GBM 
patients (Vauleon et al., 2010). Several clinical trials were conducted to evaluate the 
efficacy of cytotoxic T lymphocytes (CTL) on High Grade Glioma patients. Cytotoxic T 
Lymphocytes were delivered to the cerebrum by direct injection into the tumor site 
(Vauleon et al., 2010). In some clinical trials, cytotoxic T lymphocytes were generated 
from lymph nodes or peripheral blood mononuclear cells and were combined with 
vaccination strategy in 65 patients. The combination strategy of both immune cells were 
delivered to the tumor site either by intravenous injection or by intracarotid infusion. The 
reported side effects include a hypersensitivity reaction at the injection site. The degree of 
tolerance was acceptable and no disease progression was reported (Vauleon et al., 2010).  
Ninety-five patients were treated with this combination therapy and were assessed as 
follows: 18 patients with a stable disease state, 28 patients with partial response, and 
three patients with complete response. One clinical trial has reported a survival time up to 
eight months in seven of 15 patients and up to 40 months in one patient (Holladay, Heitz-
Turner, Bayer, & Wood, 1996). 
 
2.13 Active Immunotherapy  
There are different cells such as intact tumor cells, tumor protein lysates, tumor-
derived mRNA, and natural and synthetic peptides which can be used as antigen sources 
for the active immunotherapy. Antigens can be used alone or with dendritic cells and 




          Autologous tumor cells (ATC) was used as vaccines in several clinical trial studies 
for the treatment of High Grade Glioma patients. The cells are injected either 
subcutaneously or intradermally. Several clinical studies reported that the vaccination 
procedure should be repeated for three cycles with a total of one to 13 injections. Side 
effects include fever, erythema, and abnormal liver tests (Vauleon et al., 2010). Fifty- 
three high Grade Glioma patients were enrolled in several clinical studies based on the 
treatment with autologous tumor cells and the patients were assessed as follows: four 
patients with complete response, six patients with partial response, two patients with 
minor response, and six patients with stable disease.  
Vaccination based on dendritic cells is very useful for the treatment of GBM 
especially for patients with small tumors. The antigens were derived from tumor lysates, 
peptides or mRNA that are obtained from autologous tumor cells ATC or the whole ATC 
in several clinical studies. Tolerance was manageable with the rare incidence of grade 
four neurotoxicity (Yamanaka et al., 2005).  Side effects include; headache, seizure, and 
flu-like syndrome. This treatment strategy was found to initiate a peripheral immune 
response in large percent of patients who were enrolled in the clinical studies.  
Further investigation on a number of patients who received vaccination showed 
that CD8 lymphocytes were specifically expressed. The analysis of the radiological 
response of c Thirty-four Glioblastoma patients who have responded to the vaccination 
??????????????????? ??????????????????????????????????????????????????????????????s 
detected in nonresponsive patients. The responded patients also experienced an enhanced 
response to the chemotherapy which was administered in a second phase (Wheeler et al., 




adaptive immune system to produce immune response and eradicate tumor cells (Wang et 
al., 2014).  
  Early vaccinated Glioblastoma patients with high intratumoral infiltration by T 
lymphocytes were found to experience a small level of intratumo?????????? longer 
survival. Patients with major tumors who were vaccinated late showed no infiltration in T 
lymphocytes, experienced high levels of intratumo??????????????????????????????????
months of overall survival (Liau et al., 2005). Glioblastoma patients who have received 
mature dendritic cells achieved longer survival than patients who have received immature 
dendritic cells. The co- administration of both peripheral and intracranial dendritic cells 
showed a more optimum response than peripheral injection only (Yamanaka et al., 2005).    
A combined therapy of dendritic cells (DC) that was obtained from monocytes and 
temozolomide in a primary treatment course of therapy was tested on 14 Glioblastoma 
patients. Two patients were reported with positive antitumor immune responses in the 
peripheral blood (Hunn et al., 2015). 
 
2.14 DC Development, Diversification, Maturation, and Function 
 Dendritic cells (DCs) are antigen presenting cells, which have the ability to 
stimulate the native T cells and induce primary immune responses and peripheral 
immunological tolerance. Immature DCs (im DCs) originates from hematopoietic stem 
cells within the bone marrow. The process of development and diversification of DCs is 
antigen-independent. CD34+ hematopoietic stem cells differentiate into common myeloid 
progenitor cells (CMP) and common lymphoid progenitor cells (CLP). The CMPs 




CLA+ cells differentiate into CD11c+ CD1a+ Langerhans cell precursors, CD34+CLA-
cells differentiate into CD11c+ CD1a- interstitial DC precursors in blood. The blood 
CD11c+ CD1a+ Langerhans cell precursors migrate into the skin epidermis and become 
Langerhans cells and the CD11c+CD1a- migrate into the skin dermis and other tissues to 
become interstitial DCs. In case of the absence of antigen/pathogen stimulation, both 
Langerhans cells and interstitial DCs play a critical role in immune tolerance in the 
lymph nodes. After being stimulated by microbes, Langerhans cells and interstitial DCs 
become mature and rapidly induce primary immune responses. CMP and CLP also 
differentiate into Phenotype myeloid pre-DC1s and lymphoid pre-DC2s in bone marrow. 
After bacterial infection, pre-DC1s recognize and destroy bacteria, differentiate into DCs, 
and initiate adaptive antibacterial immune responses. After viral infection, pre-DC2s 
triggers the production of type-1 IFN, differentiate into DCs, and initiate adaptive 










Tyrosinase-???????????????????????, AIM-2 (Zhang et al., 2007; ????-?????????, gp100, 
MAGE1, and ??????????????????????????-chain IL13Ra2 (Zhang et al., 2007; Liu et al., 
2004; Okano, Storkus, Chambers, Pollack, & Okada, 2002).  
 Furthermore, CD133 is a stem cell marker which is overexpressed on GBM cells 
and was found to result in radio- resistance, chemo-resistance, and tumor aggressiveness. 
CD133 was found to be increased by 4.6-fold in recurrent GBM cells compared with the 
percentage in primary GBM cells (Pallini et al., 2011). Several studies have shown that 
cytomegalovirus phosphoprotein 65pp65 HCMV is also expressed in more than 90% of 
GBM specimens in contrast with normal brain (Dziurzynski et al., 2012; Cobbs et al., 
2002); which suggests that  HCMV viral proteins may be used as tumor-specific target 
(Mitchell et al., 2015).  
2.16 End Points and Evidences of Therapeutic Activity 
 
One of the primary end points is the Overall survival (OS) which was defined as 
???? time from the day of surgical tumor resection until the date of death due to any 
cause?. Another end point is the Progression-free survival (PFS) which was defined as 
?the time from the day of surgical tumor resection until the first documented progression 
in MRI or death due to any cause whichever is earlier? (Akasaki et al., 2016). 
Objective tumor response is considered as a targeted end point in some clinical 
trials. It is measured by investigating the presence of a complete response, partial 
response, progressive disease, or stable disease. Complete response (CR) is defined as the 




50 % reduction in tumor size for 4 weeks. Progressive disease (PD) is defined as 25 % 
increase in tumor size or appearance of new lesions. Stable disease (SD) is neither PD or 
PR as shown in 2D categorization criteria shown in table 2.3 (Miller, Hoogstraten, 
Staquet, & Winkler, 1981). 
Table 2.3 1D and 2D response categorization criteria (Shah et al., 2006). 
Method Response Category 
% CR % PR % SD % PD 
1D 100  >30 30 to 20 >20 
2D 100        >50 25 to 25 >25 
 
2.17 Nanotechnology in Immunotherapy for GBM 
There is a great need for an optimized therapy for the treatment of GBM. 
Although, immunotherapy is considered a potential treatment for glioblastoma, it 
still faced by major limitations such as target identification, delivery system, and 
local suppression of the immune system (Patel, Kim, Ruzevick, Li, & Lim, 2014). 
The blood brain barrier blood brain barrier BBB prevents large particles from 
penetrating into the brain to be delivered to the tumor site. Increasing the dose of 
the therapeutics will cause toxic side effects due to the decreased local 
bioavailability and the accumulation of the medicines into the vital organs 
through the reticuloendothelial system (Ung & Yang, 2015). Nanotechnology can 
be used to increase the efficacy of new therapeutics and decrease the toxic side 
effects (Nduom, Bouras, Kaluzova, & Hadjipanayis, 2012). The particle size, 
morphology, composition, and surface modifications of the nanoparticles can be 




shown in Figure 2.3. Nanoparticles are synthesized from carbon, lipids, or 
polymeric units can carry and deliver different active ingredients locally to the 
tumor cells and avoid normal cells. Nanoparticles can enhance the efficacy of the 
immunotherapy that is used as a potential treatment for glioblastoma Multiforme. 
Nanoparticles can selectively target interleukin-13 receptors which are 
overexpressed in the tumor cells. This mechanism of selective targeting has a 
great advantage of minimizing toxic side effects especially in the healthy tissues 
(Ung & Yang, 2015).  
Dendritic nanoparticles or dendrimers consist of large number of 
oligomeric branches and several surface groups. They can be modified due to the 
large number of branching units using a wide range of functional groups to 
improve the immunotherapy for Glioblastoma Multiforme.  Dendrimers were 
grafted to both doxorubicin and siRNA (Ofek, Fischer, Calderón, Haag, & Satchi-
Fainaro, 2010). Dendritic nanoparticles achieved high degree of selectivity and no 
cytotoxicity effects were reported. The use of siRNA loaded in a nanoparticle is 
considered a potential treatment especially in the gene therapy approach for the 
treatment of GBM (Ofek, Fischer, Calderón, Haag, & Satchi-Fainaro, 2010). 
Nanoparticles is a potential solution which can be used to overcome the major 
limitations of the immunotherapy for GBM. They exhibit a great ability to attach 
efficiently with the targeted sites, deliver different treatments in a concentrated 
and controllable manner to the tumor tissues, and reducing the toxic side effects 






Figure 2.7 Different shapes and compositions of nanoparticles that are used in drug 




              This chapter has provided an overview to the review of relevant literature. It has 
provided Glioblastoma Multiforme (GBM), epidemiology, metastases, cancer stem cell 
????????????????????????????????????????????????????????, and ?????????????? 
immune reactions in healthy brain and in Glioblastoma patients, immunotherapy for the 
treatment of GBM, adoptive immunotherapy, active immunotherapy, DC development, 
diversification, maturation, and function and nanotechnology in immunotherapy for the 
treatment of GBM. It also has introduced an overview of the tumor associated antigens 





CHAPTER 3. METHODOLOGY  
This chapter provides the methodology of investigating the DC- based vaccination 
immunotherapy option for GBM that includes data collection procedures, data sources, 
and data analysis techniques. 
 
3.1 Data Collection 
This study is conducted to explore the clinical outcomes of DC vaccines; which are 
currently under investigation for the treatment of GBM. Clinical trials showed that 
treating GBM patients with surgery, TMZ, and Dendritic Cell DC vaccines was safe and 
achieved meaningful clinical outcomes. The sources of antigen that have been used in DC 
immunotherapy include exogenous MHC-restricted peptides, acid-eluted tumor peptides, 
tumor cell lysate, and whole glioma cells. The study is exploring the efficiency of the 
treatment combination of immunotherapy, chemotherapy, following surgical resection of 
the tumor mass based on OS and PFS values. Data about the inclusion criteria of GBM in 
published clinical trials, pre and post vaccination treatment strategies, antigen sources, 
and immune responses that are related to the relatively most preferable clinical outcomes 
(OS and PFS) has been considered.  
3.2 Data Sources  




? The official site of the Food and Drug Administration Agency. 
? The official site of the European Medicines Agency. 
? Clinical trials websites. 
? The published literature of the clinical trials; which were conducted on GBM 
patients. 
3.3 Data Analysis 
An independent samples t-test has been used to compare the means of OS and 
PFS values of independent sample groups of GBM patients. Data has been collected from 
published results of the clinical trials conducted on GBM patients who were involved in 
different treatment strategies. Moreover, ANOVA test has been performed to compare 
the means of OS and PFS values of two or more independent sample groups of GBM 
patients and to show graphical displays.  
The first independent samples t-test has been performed to determine the presence 
of a statistically significant difference of OS and PFS values between 2 groups of 
patients. The first group received DC based vaccination pulsed with specific antigens 
(SA) with concomitant or post vaccination TMZ. The sources of SA antigens include the 
synthetic class I peptides AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2 or 
the synthetic peptides TRP-2, gp100, her-2/neu, and survivin. The second group received 
DC based vaccination loaded with tumor material antigens (TM) and concomitant or post 
vaccination TMZ. The sources of TM antigens include autologous tumor or glioma cells.  
The second independent samples t-test has been performed to determine the 
presence of a statistically significant difference of OS and PFS values between two 




vaccination TMZ and did not receive pre-vaccination TMZ (Nil). The second group have 
received pre-vaccination TMZ + DC vaccine + concomitant or post-vaccination TMZ 
(TMZ).  
The third independent samples t-test has been performed to determine the 
presence of a statistically significant difference of OS values between two groups of 
GBM patients. The first group received pre-vaccination TMZ + RT + DC vaccine + 
concomitant or post-vaccination TMZ (TMZ+RT). The second group of GBM patients 
DC vaccine + concomitant or post vaccination TMZ and did not receive pre-vaccination 
therapy (Nil). 
The fourth independent samples t-test has been performed to determine the 
presence of a statistically significant difference of PFS values between two groups of 
GBM patients. The first group received pre-vaccination TMZ + RT + DC vaccine + 
concomitant or post-vaccination TMZ (TMZ+RT). The second group of GBM patients 
received DC vaccine + concomitant or post vaccination TMZ and did not receive pre-
vaccination therapy (Nil). 
ANOVA test has been performed to determine the presence of a statistically 
significant difference between the means of OS and PFS values of two groups of GBM 
patients. The first group includes patients who received DC based vaccination + 
concomitant or post-vaccination TMZ with or without RT. The second group includes 







This chapter has presented the different elements of the research methodology. It 






CHAPTER 4. DATA COLLECTION, DATA ANALYSIS, AND FINDINGS 
This chapter presents the data which has been collected to investigate the clinical 
outcomes of using different DC- based vaccination strategies, immune responses that are 
accompanied by the most preferable clinical outcomes, data analysis, and findings. 
 
 
4.1 Data Collection 
 
????????????????????????????????????????????????????????????????????????????????????
post vaccination treatment strategies, antigen sources, immune responses that are related 
to the relatively most preferable clinical outcomes (OS and PFS) have been collected. 
 
 
4.1.1 Clinical Outcomes  
 
Different clinical outcomes were associated with DC- based vaccination therapy 
loaded with different antigens which were obtained from different antigen sources. The 
sources of antigen that have been used in DC immunotherapy include synthetic class I 
peptides AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2, synthetic peptides 
TRP-2, gp100, her-2/neu, and surviving, and autologous tumor or glioma cells. Clinical 
trials showed that treating GBM patients with surgery, TMZ, and Dendritic Cell DC 




widely used end point in clinical trials. Different values of OS and PFS reached 
by GBM patients involved in different treatment strategies have been investigated. 
 
4.1.1.1 Conventional Treatment with TMZ+RT 
  
Data were obtained from the (EORTC 26981/22981) phase 3 clinical trial; which was 
conducted to prove the efficacy and safety of TMZ combined with RT in comparison to RT 
alone. This trial included 573 patients, 287 were treated with RT+TMZ and 286 patients were 
treated with RT alone. Kaplan Meier curves show the survival distributions achieved with RT + 
TMZ. The median overall survival was 14.6 months and the median PFS was 6.9 months for 
patients who were treated with TMZ+RT. 61% of GBM patients reached 1-year OS and 26% 
achieved 2 years OS after being treated with RT + TMZ. The efficacy results are shown in figure 
4.1 and figure 4.2 (EMA, n.d.). 
 









4.1.1.2 DC Vaccine improves Responses to Chemotherapy 
 
The treatment of GBM patients with DC vaccine in combination with standard 
adjuvant therapy has showed safety and efficacy. The values of overall survival of 13 
patients with malignant astrocytoma who were treated with DC vaccination and 
conventional therapy are shown in table 4.1. The age of recruited patients varied between 
1?75, the performance status ECOG (Eastern Cooperative Oncology Group) was 0, 1 or 2 
(Walker et al., 2008). The ECOG performance status of 0, 1, and 2 is equivalent to ? 70% 
of Karnofsky performance status (Oken et al. 1982). Three out of eight GBM patients had 
progressive disease and five patients showed an objective radiological response to 
treatment. One patient showed a complete response, which persisted for three months. 




demonstrated that the improvements of patient responses to adjuvant chemotherapy were 
related to the use of DC vaccines (Walker et al., 2008). 
 
4.1.1.3 Clinical Outcomes of the Treatment Strategy of DC Vaccine loaded with Tumor 
Material (TM) and Chemotherapy 
 
 A phase 1 clinical study showed that treating GBM patients with surgery, TMZ, 
autologous tumor material loaded DC vaccines, and further TMZ was safe and achieved a 
limited efficacy as shown in table 4.2. Information regarding enrolled patients and 
previous treatment strategies are shown in Table 4.3. The 6 months PFS for all treated 
patients (n =9) was 22 % which is similar in the combined treatment and the treatment 
with TMZ alone.  The median OS from the original diagnosis of GBM for the treated 
patients was 23 months. No grade IV toxicities or DC related toxicity were detected. The 
reported adverse events of the combined therapy were only attributed to the anticipated 
toxicity of TMZ (Hunn et al., 2014). 
 
A clinical trial was designed to evaluate the safety and clinical responses of two 
groups of GBM patients treated with a combined therapy of TMZ and fusions of DCs and 
glioma cells (FC). Group-R included patients (n = 10) with recurrent GBM patients after 
failing TMZ-chemotherapy and Group-N included newly diagnosed GBM patients (n = 
22). The selection criteria included ?????????????????????????????????????????????? ?????
the age average was 54.6 years.The medians, first quartiles, third quartiles, and 95 % 





Table 4.1The results of a phase I dendritic cell vaccine and standard adjuvant therapy 





Table 4.2 The clinical outcomes of using TMZ + monocyte-derived dendritic cells (DC) 
pulsed with autologous tumor cells (Hunn et al., 2014).  
Patient Vaccination 
Received 
(Prime + Boost) 
Cycles of TMZ 
Received 





A01 3+6 6 31.5 40 
A02 3+3 4 5 7 
A05 3+3 4 2 7 
A06 3+5 4 6 10 
A08 3+6 6 12.3 14 
A09 3+2 2 3 7.8 
A12 3+3 3 5.3 6 
A13 3+2 2 2 7.8 











Figure 4.3 The Kaplan?Meier curves of a PFS and b OS of recurrent GBM patients, c 
PFS and d OS of newly diagnosed GBM patients after being treated with TMZ and FC 




  The phase 1 clinical trial was conducted on 34 patients with malignant glioma and 
treated with autologous tumor lysate-pulsed DC (ATL-DC) (28 patients). The study 
demonstrated the absence of dose-limiting toxicity on GBM patients. Clinical outcomes 
which were expressed as PFS and OS values are shown in table 4.5 (Prins et al., 2013). 
4.1.1.4 Clinical Outcomes of the Treatment Strategy of DC Vaccine loaded with Tumor 
Specific Antigens (SA) and Chemotherapy 
 ICT-107 is an autologous vaccine consisting of patient DC pulsed with six 
synthetic class I peptides (AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2). 
These antigens are known tumor specific antigens and some of them are overexpressed 
on Cancer Stem Cells CSCs. A single-arm phase I study was conducted on 21 GBM 
patients whose tumors expressed at least three of these antigens. Patients with newly 
diagnosed and recurrent GBM who had their tumor resected and received a standard 
treatment of TMZ and RT were recruited. Patients were treated with ICT-107 vaccine to 
investigate its immunogenicity, safety and efficacy. After receiving DC based 
vaccination, patients with newly diagnosed GBM received TMZ and patients with 
recurrent GBM received TMZ with or without bevacizumab. Clinical outcomes were 
evaluated as PFS and OS in months as shown in table 4.4 (Phuphanich et al., 2012). 
Median PFS in newly diagnosed patients was 16.9 months, and median OS was 
38.4 months. 55.6 % of the treated patients reached three-year overall survival. The 











Figure 4.4 The Kaplan?Meier probability curves of (a) PFS and (b) OS of GBM patients 






The phase 2 clinical trial has been conducted to determine the safety, efficacy, 
and the ability to stimulate the immune response of 124 GBM patients of ICT-107 after 
surgery and chemotherapy. A phase 3 clinical trial is also under investigation 
(Clinicaltrials.gov, 2016). 
 The phase 1 clinical trial was conducted on 34 patients with malignant glioma and 
treated with glioma-associated antigen peptide-pulsed DC vaccination (GAA-DC) (six 
patients). The study demonstrated the absence of dose-limiting toxicity on GBM patients. 
The trial used the synthetic peptide antigens TRP-2, gp100, her-2/neu, and survivin 
which are known to be expressed by gliomas (Andersen et al., 2013; Zhang et al., 2008). 
Clinical outcomes which were expressed as PFS and OS values are shown in table 4.5 
(Prins et al., 2013). 
 
4.1.2 Immune Responses and Prognostic Biomarkers 
 Assays that measure the immune responses are crucial for the detection of anti-
tumor responses that were developed after DC vaccine. Different tumor specimen 
analysis and assays such as the immunohistochemical analysis and CTL assays have been 
performed in clinical trials to determine immune responses that are strongly related to 







Table 4.5 OS, PFS, and clinical characteristics of GBM patients who were either treated 




4.1.2.1 Tumor-Specific Cytotoxic T Lymphocyte CTL Responses 
 
 CTL assays were used to determine systemic tumor-specific cytotoxicity in GBM 
patients who received dendritic cell vaccine pulsed with acid-eluted tumor peptides as 
shown in figure 4.5. Patients who developed post-vaccination peripheral tumor-specific 
CTL activity have reached longer survival and did not experience progressive disease in 





Figure 4.5 Peripheral CTL responses to autologous DC vaccine pulsed with acid-eluted 
tumor peptides. Negative CTL in patient (A) and positive CTL in patient (B) (Liau et al., 
2005). 
  
The up-regulation of several glioma-associated antigens such as WT-1 (M. Y. 
Chen et al., 2010), gp-100 (Xie, Nguyen, Hupe, & Wei, 2009), and MAGE-A3 (Monte et 
al., 2006) makes the tumor cells resistant to chemotherapy. These antigens are known as 
chemo resistance associated peptides (CAPs). The assessment of CTL responses against 
these TAAs was performed to investigate the correlating with OS as shown in figure 4.6. 
Antigen-specific CTL responses against WT-1 (a), gp-100 (b), and MAGE-A3 (c) were 





The OS was 17.8 months in patient 1, 21.2 months in patient 2 , > 36 months in 
patient  3, and reached > 48 months in patient 4 (Akasaki et al., 2016) . 
 
 
Figure 4.6 Expression of WT-1, gp-100, and MAGE-A3 in 4 GBM patients (Akasaki et 
al., 2016). 
 
4.1.2.2 CD3+, Tumor-Infiltrating Lymphocytes (TIL), and Transforming Growth 
Factor-???????? 
 
 Immunohistochemical analysis of tumor specimens from the pre-vaccination and 
post-vaccination surgery has been performed. Cytotoxic T cells CD8+ and memory T 
cells (CD45RO) infiltrates were found to be elevated in all post-vaccination specimens 
compared with the pre-vaccination specimen. The elevation of cytotoxic T cells CD8+ 





Figure 4.7 Cytotoxic T cells CD8+ (dark cells) in malignant astrocytoma tissue before 
DC vaccination (a), and after DC vaccination (b) (Walker et al., 2008) .  
 
  
 Patients with robust infiltration of CD3+ and tumor-infiltrating lymphocytes (TIL) 
such as CD8+, CD45RO+ memory T cells, and CD4+ helper T cells reached >30 months 
OS as shown in figure 4.9 (A and B). Those patients also had lower expression of 
transforming growth factor-?? ?????????????????M cells samples as shown in figure 4.8. 
The accumulation of TGF-???????????????????? ???????????????? ?????????????????
absence TIL infiltration and a clinically significant antitumor immune response in GBM 
patients. Patients with no significant difference in the infiltration of TIL as shown in 
figure 4.9 (C) have experienced tumor progression and died within 1 year. Figure 4.9 (D) 
also shows a control group of GBM patients who did not receive DC vaccination (Liau et 
al., 2005). A recent study also showed a significant correlation between high TIL content 







Figure 4.8 TGF-?2 expressions in GBM specimens. Analysis of TGF-?2 mRNA (A), 
high TGF-?2 (B), low TGF-?2 protein expression (C) in GBM tissue (Liau et al., 2005). 
 
Figure 4.9 Infiltration of TIL into GBM cells after receiving DC vaccine pulsed with 






4.1.2.3 Immune Responses to Specific TAAs 
 
 Patients with optimum clinical outcomes (A01, A08) experienced baseline 
immune responses to antigens in the tumor material as well as responses to TRP-2, 
survivin and SOX-2  (Hunn et al., 2014). The two patients also had the lowest level of 
Treg at baseline and one of these also had the lowest level of putative Myeloid-Derived 
Suppressor Cells MDSC and high proportion of CD8+. One patient (A08) also had an 
unusually high proportions of CD4+ effector cells. Response categorization was based on 
the WHO UICC system (Hunn et al., 2014). 
 A significant correlation of PFS and OS with quantitative expression of MAGE1 
and AIM-2 were detected. Patients with overexpression of HER2 and gp100 reached a 
relatively long survival (Phuphanich et al., 2012). 
 
4.1.2.4 CD133 Expression 
 
 A decrease in or absence of CD133 expression was found in five patients who 
underwent a second resection. Patient (#03) experienced recurrent GBM and a decrease 
in CD133 expression after vaccination as shown in Figure 4.10. Patient (#08) had 
negative expression of CD133. Patient (#10) with a newly diagnosed disease was 
negative for CD133 in both the primary and recurrent tumor. Another patient (# 09) 
experienced a one-log decrease in CD133 expression. Patient (#19) was negative for 
CD133 in the second surgical sample and did not experience a progressive disease 










4.1.2.5 The Inhibition of Anti-Tumor Immune Responses by Treg and NK 
 
The GAA-DC trial have been encountered regulatory T cell or NK cell 
populations that inhibited anti-tumor immune responses. NK cells activated populations 
CD3-, CD16+, CD25+ were found to be significantly increased in the peripheral blood of 
patients received GAA-DC. A remarkable independent association between Treg cell 
ratios (post/pre-DC vaccination) and overall survival was also reported as shown in table 
4.6. The inhibition of Treg and activated NK cells in GBM patients following DC 





Treg ratio post/pre-DC vaccination may be considered as prognostic biomarkers 
for OS in GBM patients (Prins et al., 2013). 
Table 4.6 Stratified Cox proportional hazards model for survival with clinical endpoints 
and immune monitoring ratios (Prins et al., 2013). 
 
 
4.1.2.6 The Effect of TMZ + RT Treatment Strategy on Immune Response 
 
TMZ + RT treatment strategy was reported to selectively reduce CD4+ T cells 
which may result in the reduction of their negative effects on immune therapy. TMZ was 
also reported to cause depletion of CD4+CD25+ T-cell subsets (Su et al., 2004). The 
identified Treg cells suppress T-cell responses and the depletion of these cells has 
resulted in a significant enhancement of CD8+ T-cell immunity in animal models 





4.1.2.7 DC Migration to the Draining Lymph Nodes 
 
 A recent study showed that pre-conditioning the vaccine site with 
a potent recall antigen such as tetanus/diphtheria (Td) toxoid has been resulted in a 
significant enhancement of the lymph node homing, DC migration bilaterally, and 
improved OS. There was a significant accumulation of injected DCs in vaccine site 
draining lymph nodes (VDLNs) in patients who received Td in contrast with patients who 
received un-pulsed DCs as shown in Figure 4.11 (a). Moreover, patients received Td 
achieved a significant increase in both PFS as shown in figure 4.11 (b) and OS as shown 
in figure 4.11 (c) in contrast with the other group of patients. These findings suggest that 
DC migration should  be considered as a predictive biomarker for DC-base vaccination 
studies as well as other immunotherapy studies (Mitchell et al., 2015). 
 
Figure 4.11 Td pre-conditioning enhances DC migration to VDLNs and increase OS and 








4.2 Data Analysis and Findings 
 
??????????????????????????????????????????????????????????????????????????????????
strategies, and clinical outcomes (OS and PFS) in published clinical trials are shown in 
table 4.7.Independent samples t-tests have been used to compare the means of OS and 
PFS values of independent sample groups of GBM patients. Moreover, ANOVA test has 
been performed to compare the means of OS and PFS values of two or more independent 
sample groups of GBM patients.  
The first independent samples t-test has been performed to determine the presence 
of a statistically significant difference of OS and PFS values at 95% confidence level (? 
= 0.05) between two groups of GBM patients. The first group have received DC based 
vaccination pulsed with specific antigens (SA) with concomitant or post vaccination 
TMZ (n=22 for comparing OS and PFS). The sources of SA antigens include the 
synthetic class I peptides (AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2) on 
21 patients or the synthetic peptides (TRP-2, gp100, her-2/neu, and survivin) on six 
patients. The second group of GBM patients received DC based vaccination loaded with 
tumor material antigens (TM) and concomitant or post vaccination TMZ (n=78 for OS 
and n= 69 for PFS). The sources of TM antigens include autologous tumor or glioma 
cells. The null hypothesis is H0: µSA = µTM and the alternative hypothesis is H1: µSA > 
µTM.Test results showed that with 95% confidence level the mean of the OS and PFS 
values for the group of patients who received DC based vaccination pulsed with specific 
antigens with concomitant or post vaccination TMZ (SA) is higher than the mean of OS 




tumor material antigens and concomitant or post vaccination TMZ (TM) (p= 0.006 and 
0.002 respectively). 
Table 4.7 ??????????????????????????????????????????????????????????????????????es, OS, 























Nil TMZ (2 
cycles) 












Nil Nil 71 ш70% 2 - 
A03 Tumor 
Material 
Nil Nil 25 ш70% 4 - 
A04 Tumor 
Material 
Nil Nil 52 ш70% 5 - 
A05 Tumor 
Material 
Nil TMZ (6 
cycles) 
44 ш70% 18 - 
A06 Tumor 
Material 
Nil Nil 66 ш70% 9 - 
A07 Tumor 
Material 
Nil TMZ 47 ш70% 15 - 
A08 Tumor 
Material 
Nil TMZ 60 ш70% 11 - 
A09 Tumor 
Material 
Nil TMZ (2 
cycles) 














































































































TMZ + RT TMZ 46 90% 60.95 60.95 
A21 Specific 
Antigens 
TMZ + RT TMZ 56 100% 66.51 66.51 
A22 Specific 
Antigens 
TMZ + RT TMZ 61 90% 60.1 60.1 
A23 Specific 
Antigens 
TMZ + RT TMZ 51 90% 19.53 6.87 
A24 Specific 
Antigens 
TMZ + RT TMZ 47 90% 53.03 15.98 
A25 Specific 
Antigens 
TMZ + RT TMZ 53 905 25.91 12.62 
A26 Specific 
Antigens 
TMZ + RT TMZ 65 90% 22.55 8.25 
A27 Specific 
Antigens 
TMZ + RT TMZ 60 90% 38.37 29 
A28 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 49.38 49.38 
A29 Specific 
Antigens 
TMZ + RT TMZ 34 90% 48.66 48.66 
A30 Specific 
Antigens 
TMZ + RT TMZ 63 ш60% 32.42 17.72 
A31 Specific 
Antigens 
TMZ + RT TMZ 79 ш70% 15.98 11.28 
A32 Specific 
Antigens 
TMZ + RT TMZ 52 90% 33.99 8.88 
A33 Specific 
Antigens 
TMZ + RT TMZ 48 ш80% 47.64 47.64 
A34 Specific 
Antigens 
TMZ + RT TMZ 62 90% 41.82 7.27 
A35 Tumor 
material 










TMZ + RT TMZ 49 90% 34.4 18.1 
A37 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A38 Tumor 
material 




























TMZ + RT TMZ 49 90% 34.4 18.1  
A40 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A41 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A42 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A43 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A44 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A45 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A46 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A47 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A48 Tumor 
material 
TMZ + RT TMZ 49 905 34.4 18.1 
A49 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A50 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A51 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A52 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A53 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A54 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A55 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A56 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A57 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A58 Tumor 
material 




























TMZ + RT TMZ 49 90% 34.4 18.1  
A60 Tumor 
material 
TMZ + RT TMZ 49 905 34.4 18.1 
A61 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A62 Tumor 
material 
TMZ + RT TMZ 49 90% 34.4 18.1 
A63 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A64 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A65 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A66 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A67 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A68 Specific 
Antigens 
TMZ + RT TMZ 44 ш80% 14.5 9.6 
A69 Tumor 
material 











Nil TMZ 54.6 ш 50 % 30.5 18.3 
A71 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A72 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A73 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A74 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A75 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A76 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A77 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A78 Tumor 
material 




























Nil TMZ 54.6 ш 50 % 30.5 18.3  
A80 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A81 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A82 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A83 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A84 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A85 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A86 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A87 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A88 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A89 Tumor 
material 
Nil TMZ 54.6 ш 50 % 30.5 18.3 
A90 Tumor 
material 
Nil TMZ 54.6 ш 50 % 18 10.3 
A91 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A92 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A93 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A94 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A95 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A96 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A97 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A98 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A99 Tumor 
material 
TMZ TMZ 54.6 ш 50 % 18 10.3 
A100 Tumor 
material 





There is a statistically significant difference of the means of OS and PFS values between 
the two groups. DC vaccine pulsed with specific antigen that were found to be 
overexpressed on tumor cells of patients achieved more beneficial clinical outcome than 
DC vaccines loaded with tumor material. 
ANOVA test has been performed to compare the means of OS and PFS values of 
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Figure 4.13 The difference in the means of PFS values between two groups of GBM 
patients. 
The second independent samples t-test has been performed to determine the 
presence of a statistically significant difference of OS and PFS values at 95% confidence 
level (? = 0.05) between two groups of GBM patients. The first group have received DC 
vaccine + concomitant or post vaccination TMZ and did not receive pre-vaccination TMZ 
(Nil) (n=31 for OS and n= 22 for PFS). The second group of GBM patients received pre-
vaccination TMZ + DC vaccine + concomitant or post-vaccination TMZ (TMZ) (n= 19 
for OS and PFS). The null hypothesis is H0: µNil = µTMZ and the alternative hypothesis is 
H1: µNil > µTMZ. 
 Test results showed that with 95% confidence level (?=.05), the means of the OS 
and PFS values for the group of patients who received DC vaccine + concomitant or post 
vaccination TMZ and did not receive pre-vaccination TMZ (Nil) is higher than the mean 
of OS and PFS values of the group of patients who received pre-vaccination TMZ + DC 
vaccine+ concomitant or post-vaccination TMZ (P-Value = 0.001 and 0.000 













Interval Plot of PFS (months) vs Antigen Source




values between the two groups. Our result suggested that receiving pre vaccination TMZ 
had been resulted in less beneficial clinical outcomes. 
ANOVA test has been performed to compare the means of OS and PFS values of 




Figure 4.14 The difference in the means of OS values between different groups of GBM 
patients.  
 
The third independent samples t-test has been performed to determine the 
presence of a statistically significant difference of OS values at 95% confidence level (? 
= 0.05) between two groups of GBM patients. The first group received pre-vaccination 
TMZ + RT + DC vaccine + concomitant or post-vaccination TMZ (TMZ+RT, n=50). 
The second group of GBM patients DC vaccine + concomitant or post vaccination TMZ 
and did not receive pre-vaccination therapy (Nil) (n=31). The null hypothesis is H0: µ
 















Interval Plot of OS (months) vs Pre-Vaccination TMZ




Test results showed that with 95% confidence level (?=0.05), the mean of the OS 
values for the group of patients who received pre-vaccination TMZ + RT + DC vaccine + 
concomitant or post-vaccination TMZ (TMZ+RT) is higher than the mean of OS values 
for the group of patients who received DC vaccine + concomitant or post vaccination 
TMZ and did not receive pre-vaccination therapy (Nil) (P-Value = 0.000). There is a 
statistically significant difference of the means of OS values between the two groups. 
Receiving pre vaccination TMZ+RT achieved relatively more OS than receiving pre 
vaccination Nil as shown in figure 4.14. 
 The fourth independent samples t-test has been performed to determine the 
presence of a statistically significant difference of PFS values at 95% confidence level (? 
= 0.05) between two groups of GBM patients. The first group received pre-vaccination 
TMZ + RT + DC vaccine + concomitant or post-vaccination TMZ (TMZ+RT, n=50). 
The second group of GBM patients received DC vaccine + concomitant or post 
vaccination TMZ and did not receive pre-vaccination therapy (Nil, n=22). The null 
hypothesis is H0: µ
 TMZ+RT = µNil and the alternative hypothesis is H1: µ  TMZ+RT > µNil. 
Test results showed that with 95% confidence level (?=.05), the mean of the OS 
values for the group of patients who received pre-vaccination TMZ + RT + DC vaccine + 
concomitant or post-vaccination TMZ is not higher than the mean of OS values for the 
group of patients who received DC vaccine + concomitant or post vaccination TMZ and 
did not receive pre-vaccination therapy (Nil) (P-Value = 0.194). There is no statistically 
significant difference of the means of the PFS values between the two groups.  
ANOVA test has been performed to compare the means of PFS values of the two 





Figure 4.15 The difference in the means of the PFS values between different groups of 
GBM patients involved in different treatment strategies. 
 
ANOVA test has been performed with 95% confidence level (?= 0.05) to 
determine the presence of a statistically significant difference between the means of OS 
and PFS values of two groups of GBM patients. The first group includes patients who 
received DC based vaccination + concomitant or post-vaccination TMZ with or without 
RT (n=100 for OS values and n=91 for PFS values). The second group includes patients 
who received TMZ+RT with no DC vaccine (n=287). The null hypothesis is H0: µ1= µ2 
????????????????????????????????????????????? 
The test results showed that there is a statistical significant difference between the 
means of OS (P=0.00) and PFS values (P=0.00) of the two groups of GBM patients as 
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Figure 4.16 The difference of means of OS values between two groups of GBM patients.  
 
 






This chapter has presented the collected data, data analysis techniques, test results 
and findings of this research. 










Interval Plot of OS (DC+TMZ) , OS (TMZ+RT)
95% CI for the Mean










Interval Plot of PFS (DC+TMZ), PFS(TMZ+RT)






CHAPTER 5. DISCUSSION, CONCLUSION AND RECOMMENDATIONS  
 
 This chapter dis???????????????????????????????????????????????????????????? and 






 Chemotherapy and radiotherapy are immunosuppressive and may minimize the 
potential responsiveness to the cancer vaccine being tested on patients with recurrent 
diseases. The immunomodulatory effects of concomitant treatments such as 
chemotherapies should be justified and considered in the clinical trial design.  
 Anti-tumor immune response generally requires 2-3 months to be detected and 
initiate the effectiveness of a cancer vaccine.  Cancer vaccines are better to be tested in 
patients with no evidence of residual disease to provide enough time for the cancer 
vaccine to initiate an immune response that could be measured. As a result, patients may 
experience early progression followed by subsequent response, which should be 





The disadvantage of the clinical development of cancer vaccines is that it may 
require more patients and time than developing conventional therapies. This approach 
may not be able to provide interpretable evidence of efficacy because of recruiting 
patients with heterogeneous tumor types and stages. The preparation of vaccines using 
autologous patient materials is another challenge because of the differences in each 
patient and tumor histology. Heterogeneity of the patient population should be considered 
before selecting the patient population (Guidance for Industry Clinical Considerations for 
Therapeutic Cancer Vaccines, 2011). 
5.1.2 ????????????????????? for Monitoring the Immune Response 
Assays that measure the immune responses are crucial for the detection of anti-
tumor responses that were developed after DC vaccine. At least two immunological 
assays should be used to determine the targeted anti-tumor response. Assay conditions, 
sensitivity and specificity of the assay, positive and negative controls, end points for the 
assessment of results, and the statistical analytical methods should be considered as 
important parameters and identified before starting clinical trials (Guidance for Industry 
Clinical Considerations for Therapeutic Cancer Vaccines, 2011).  
5.2 Conclusion and Research Results 
 
 Current treatment options including surgery, radiotherapy, and temozolomide 
chemotherapy are associated with limited clinical benefits. The median OS reached by 
GBM patients was approximately 12 months only after being treated with radiotherapy 




months in patients who received the combined treatment of radiotherapy and 
chemotherapy with temozolomide. 
 There is a great need for an optimized therapy for the treatment of GBM. Dendritic 
Cells DCs are the most potent antigen presenting APCs in the immune system. DCs have 
the ability to capture and process neoantigens; which are formed and released by 
oncogenesis. DCs present the captured antigens on Histocompatibility Complex I and II 
(MHCI and MHCII) molecules to stimulate the native T cells and induce primary 
immune responses and peripheral immunological tolerance. After T cell responses 
against the cancer-specific antigens are primed and activated, T cells infiltrate the tumor 
bed, specifically recognize, bind to, and kill their target cancer cell. Clinical trials showed 
that treating GBM patients with surgery, TMZ, and Dendritic Cell DC vaccines was safe 
and achieved meaningful clinical outcomes. Different clinical outcomes and immune 
responses were associated with DC- based vaccination therapy. The sources of antigen 
that have been used in DC immunotherapy include synthetic class I peptides AIM-2, 
MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2, synthetic peptides TRP-2, gp100, 
her-2/neu, and surviving, and autologous tumor or glioma cells. 
Our study showed that the treatment strategy of DC-based vaccination combined 
with chemotherapy with or without RT has proved to achieve substantial clinical benefits. 
The median of OS and PFS of GBM patients who received DC vaccines combined with 
conventional treatments were 27.5 months and 17.5 months respectively. However, the 
median of OS and PFS of GBM patients who received conventional treatments of 





This research also has showed a proof of evidence that clinical outcomes of 
different DC- based vaccination therapy for the treatment of GBM patients vary based on 
the sources of antigens and different pre-vaccination strategies. DC vaccines were loaded 
with Tumor Material, pulsed with different Tumor Associated Antigens TAAs, and 
combined with different pre and post vaccination treatment strategies. These variables 
resulted in different clinical outcomes and different levels of immune responses. DC 
vaccine pulsed with specific synthetic antigens that were found to be expressed in tumor 
cells of GBM patients achieved more beneficial clinical outcome than DC vaccines 
loaded with tumor material. Receiving pre vaccination TMZ has resulted in less 
beneficial clinical outcomes (OS and PFS) than receiving DC vaccine without pre-
vaccination TMZ. Receiving pre vaccination TMZ+RT achieved relatively longer OS 
than receiving DC vaccine without pre-vaccination TMZ. However, there was no 
evidence of a meaningful improvement of PFS with the pre-vaccination treatment 
strategy of TMZ+RT. 
Assays that measure the immune responses are crucial for the detection of anti-
tumor responses that were developed after vaccination with DCs. Different tumor 
?????????? analysis and assays such as the immunohistochemical analysis and CTL 
assays have been performed in clinical trials to determine immune responses that were 
strongly related to the relatively long OS and PFS. There were many immune responses 
that were related to the most beneficial clinical outcomes; which can be considered as 
prognostic biomarkers of GBM. Patients who developed post-vaccination peripheral 
tumor-specific CTL activity have reached longer survival and did not experience 




Robust infiltration of CD3+ and tumor-infiltrating lymphocytes (TIL) such as CD8+, 
CD45RO+ memory T cells, and CD4+ helper T cells in post-vaccination specimens was 
found to be related to long OS. Antigen-specific CTL responses against specific antigens 
such as WT-1, gp-100, MAGE-A3, TRP-2, survivin and SOX-2 were also found to be 
related to a relatively long OS after vaccination with DC-based vaccination treatment. 
Lower expression of transforming growth factor-?? ??????????????????????????found 
to be related to long OS. low level of Treg and putative Myeloid-Derived Suppressor 
Cells MDSC at baseline was found to be related to beneficial clinical outcomes. 
Moreover, the enhancement of DCs migration to the draining lymph nodes was also 
associated with a significant increase in both PFS and OS. Treg ratio post/pre-DC 
vaccination, DC migration to the draining lymph nodes, and the expression of TGF????
MDSC, and CD133 should be considered as prognostic biomarkers for DC-based 
vaccination studies. 
The expression of the stem cell marker CD133 and specific Tumor Associated 
Antigens TAAs such as WT-1, gp-100, and MAGE-A3 on GBM cells was found to result 
in resistance to RT and chemotherapy and significant increase in tumor aggressiveness. 
Cytomegalovirus phosphoprotein 65pp65 HCMV was also found to be expressed in more 
than 90% of GBM specimens in contrast with normal brain. CD133, WT-1, gp-100, 
MAGE-A3, and HCMV viral proteins may be used as tumor-specific targets.  
 
5.3 Future Recommendations  
Future studies should investigate the rate-limiting steps that negatively affect the 
production of antitumor immune responses. Overcoming this problem will enhance the 
76 
effectiveness of DC vaccines and other immunotherapies. As we previously mentioned in 
the data analysis section, loading DCs with specific antigens that were found to be 
overexpressed in GBM cells has achieved substantial clinical outcomes. There is a great 
need to identify a set of antigens that is expressed in all GBM patients. Targeting those 
antigens will introduce an optimized DC-based vaccination therapy that will successfully 







LIST OF REFERENCES 
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. 
(2013). Glioblastoma, a brief review of history, molecular genetics, animal 
models and novel therapeutic strategies. Archivum Immunologiae et Therapiae 
Experimentalis, 61(1), 25?41. 
AIM-?????????????????????????????????????????????????????????????????????????




???????????????????????????????????????????????? ??????????????????????? ? ?????????
Y. (2016). Phase I/II trial of combination of temozolomide chemotherapy and 
immunotherapy with fusions of dendritic and glioma cells in patients with 
glioblastoma. Cancer Immunology, Immunotherapy, 1?11. 
https://doi.org/10.1007/s00262-016-1905-7 
Andersen, R. S., Andersen, S. R., Hjortsø, M. D., Lyngaa, R., Idorn, M., Køllgård, T. M., 
??????????????????????????? frequency of T cells specific for cryptic epitopes in





Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-???? ?????????????
(2000). Immunobiology of dendritic cells. Annual Review of Immunology, 18(1), 
767?811. 
Bartholomäus, I., Kawakami, N., Odoardi, F., Schläger, C., Miljkovic, D., Ellwart, J. W., 
???????????????????????????????????????????????????? ?????????????????????????????
in nascent autoimmune CNS lesions. Nature, 462(7269), 94?98. 
Bellail, A. C., Hunter, S. B., Brat, D. J., Tan, C., & Van Meir, E. G. (2004). 
Microregional extracellular matrix heterogeneity in brain modulates glioma cell 
invasion. The International Journal of Biochemistry & Cell Biology, 36(6), 1046?
1069. 
??????????????????????????????????????????? ????????????????????????????????????? ?????????
(2008). Phase I trial and pharmacokinetic study of bevacizumab in pediatric 
??????????????????????????????????????????????????????????????????????????
Journal of Clinical Oncology, 26(3), 399?405. 
??????????????????????????????? ???????????????????? ????????????????????????????? ?
Rustin, G. J. (1998). Phase I trial of temozolomide using an extended continuous 









Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & 
Fenart, L. (2007). Modelling of the blood?brain barrier in drug discovery and 
development. Nature Reviews Drug Discovery, 6(8), 650?661. 
https://doi.org/10.1038/nrd2368 
Chen, D.S., Irving, B.A., and Hodi, F.S. (2012). Molecular pathways: next-generation 
immunotherapy?inhibiting programmed death-ligand 1 and programmed death-
1. Clin. Cancer Res. 18, 6580?6587. 
Chen, D. S., & Mellman, I. (2013). Oncology Meets Immunology: The Cancer-Immunity 
Cycle. Immunity, 39(1), 1?10. https://doi.org/10.1016/j.immuni.2013.07.012 
?????? ????????????????????????????????? ?????????????????????????????????????????? ?
?????????? ????????????? ????????????????????????????????????????????????????
chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-
repression. Journal of Neuro-Oncology, 103(1), 87?102. 
https://doi.org/10.1007/s11060-010-0374-7 
Chiang, A. C., & Massagué, J. (2008). Molecular basis of metastasis. New England 
Journal of Medicine, 359(26), 2814?2823. 
Cobbs, C. S., Harkins, L., Samanta, M., Gille??????????????????????????????????????? ?
Britt, W. J. (2002). Human Cytomegalovirus Infection and Expression in Human 
Malignant Glioma. Cancer Research, 62(12), 3347?3350. 
Cohen, M. H., Johnson, J. R., & Pazdur, R. (2005). Food and Drug Administration Drug 
approval summary: temozolomide plus radiation therapy for the treatment of 





Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009). FDA drug approval 
summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma 
multiforme. The Oncologist, 14(11), 1131?1138. 
Dalton, W. S., & Friend, S. H. (2006). Cancer biomarkers?an invitation to the table. 
Science, 312(5777), 1165?1168. 
Davies, D. C. (2002). Blood?brain barrier breakdown in septic encephalopathy and brain 
tumours*. Journal of Anatomy, 200(6), 639?646. 
Dieckmann, K. U. (2010). Radiotherapy of glioblastoma. Memo-Magazine of European 
Medical Oncology, 3(3), 12?14. 
Dirks, P. B. (2001). Glioma migration: clues from the biology of neural progenitor cells 
and embryonic CNS cell migration. Journal of Neuro-Oncology, 53(2), 203?212. 
Dziurzynski, K., Chang, S. M., Heimberger, A. B., Kalejta, R. F., McGregor Dallas, S. 
?????????? ??? ?????????????????????????????????????e role of human 
cytomegalovirus in glioblastoma. Neuro-Oncology, 14(3), 246?255. 
https://doi.org/10.1093/neuonc/nor227 




Endersby, R., & Baker, S. J. (2008). PTEN signaling in brain: neuropathology and 





Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., 
???????????????? ??????????????????????????????????????????????-repair gene 
MGMT and the clinical response of gliomas to alkylating agents. New England 
Journal of Medicine, 343(19), 1350?1354. 
European Medicines Agency (2014). Refusal of a change to the marketing authorization 
for Avastin (bevacizumab) 
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/
human/000582/WC500167544.pdf 
Faraji, A. H., & Wipf, P. (2009). Nanoparticles in cellular drug delivery. Bioorganic & 
medicinal chemistry, 17(8), 2950-2962. 
Farrell, C. J., & Plotkin, S. R. (2007). Genetic causes of brain tumors: neurofibromatosis, 
tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurologic Clinics, 
25(4), 925?946. 
FDA Briefing Document Oncology Drug Advisory Committee Meeting (2010). 
http://www.fda.gov/downloads/Adviso...rugsAdvisoryCommittee/UCM219224.p
df. 2016.11.05 
FDA (2006). TEMODAR 6 (temozolomide) CAPSULES product Information. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021029s012lbl.pdf. 
2016.11.05. 
Ferguson, T.A., Choi, J., and Green, D.R. (2011). Armed response: how dying cells 
influence T-cell functions. Immunol. Rev. 241, 77?88. 






Chouaib, F. (2013). CD103 or LFA-1 engagement at the immune synapse 
between cytotoxic T cells and tumor cells promotes maturation and regulates T-
cell effector functions. Cancer Res. 73, 617?628. 
Franciszkiewicz, K., Boissonnas, A., Boutet, M., Combadie`re, C., and MamiChouaib, F. 
(2012). Role of chemokines and chemokine receptors in shaping the effector 
phase of the antitumor immune response. Cancer Res. 72, 6325?6332. 
????????????????????????? ?????? ??????????? ???????????????????????????????????????? ?
others. (2009). Bevacizumab alone and in combination with irinotecan in 
recurrent glioblastoma. Journal of Clinical Oncology, 27(28), 4733?4740. 
Gaudreault, J., Bruno, R., Kabbinavar, F., Sing, A., Johnson, D. H., & Lu, J. (2004). 
Clinical pharmacokinetics of bevacizumab following every 2-or every 3-week 
dosing. In ASCO Annual Meeting Proceedings (Vol. 22, p. 3041). Retrieved from 
http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/3041 
???????? ?????? ????????????????????? ?????????????? ??????????????????????????????? ?
Adelman, D. C. (2001). Phase I safety and pharmacokinetic study of recombinant 
human anti-vascular endothelial growth factor in patients with advanced cancer. 
Journal of Clinical Oncology, 19(3), 843?850. 
Greaves, P., and Gribben, J.G. (2013). The role of B7 family molecules in hematologic 






Gururangan, S., Chi, S. N., Poussaint, T. Y., Onar-Thomas, A., Gilbertson, R. J., 
??????????????? ??????????????????????????????????????????????????????
irinotecan in children with recurrent malignant glioma and diffuse brainstem 
glioma: a Pediatric Brain Tumor Consortium study. Journal of Clinical Oncology, 
28(18), 3069?3075. 
Guidance for Industry Clinical Considerations for Therapeutic Cancer Vaccines (2011). 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe
gulatoryInformation/Guidances/Vaccines/UCM278673.pdf. 
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-?????????????????????????????? ?
Stupp, R. (2004). Clinical trial substantiates the predictive value of O-6-
methylguanine-DNA methyltransferase promoter methylation in glioblastoma 
patients treated with temozolomide. Clinical Cancer Research, 10(6), 1871?1874. 
Herbst, R., Heymach, J., & Lippman, S. (2008). Molecular origins of cancer. N Engl J 
Med, 359(13), 1367?80. 
Higginson, J. (1987). Everything is a carcinogen? Regulatory Toxicology and 
Pharmacology, 7(1), 89?95. 
Holland, E. C. (2000). Glioblastoma multiforme: the terminator. Proceedings of the 
National Academy of Sciences, 97(12), 6242?6244. 
?????????????????????? ?????? ????????????????????? ??????????????????????????????? ?
Gaudreault, J. (2001). Population pharmacokinetic (PK) analysis of bevacizumab 





Hunn, M. K., Bauer, E., Wood, C. E., Gasser, O., Dzhelali, M., Ancelet, L. R., ... & 
Hermans, I. F. (2015). Dendritic cell vaccination combined with temozolomide 
retreatment: results of a phase I trial in patients with recurrent glioblastoma 
multiforme. Journal of neuro-oncology, 121(2), 319-329. 
?????? ????????????????? ?????????????????????????????????? ??????????????????? ?
Hermans, I. F. (2014). Dendritic cell vaccination combined with temozolomide 
retreatment: results of a phase I trial in patients with recurrent glioblastoma 
multiforme. Journal of Neuro-Oncology, 121(2), 319?329. 
https://doi.org/10.1007/s11060-014-1635-7 
?????????????????????????????????????????????????????????????????? ??? ?????????????? ?
Adema, G. J. (2009). Regulatory T cells and the PD-L1/PD-1 pathway mediate 
immune suppression in malignant human brain tumors. Neuro-Oncology, 11(4), 
394?402. 
Jarrod Predina, Evgeniy Eruslanov, Brendan Judy, Veena Kapoor, Guanjun Cheng, 
Liang-?????? ????? ???????????????????????????????????????????????????
microenvironment in recurrent cancers may explain the failure of vaccines after 
surgery. Proceedings of the National Academy of Sciences of the United States of 
America., 110(5), E415?E424. https://doi.org/10.1073/pnas.1211850110 
Jellinger, K. (1978). Glioblastoma multiforme: morphology and biology. Acta 
neurochirurgica, 42(1-2), 5-32. 
Jelsma, R., & Bucy, P. C. (1967). The Treatment of Glioblastoma Multiforme of the 





Kanaly, C. W., Ding, D., Heimberger, A. B., & Sampson, J. H. (2010). Clinical 
applications of a peptide-based vaccine for glioblastoma. Neurosurgery Clinics of 
North America, 21(1), 95?109. 
Karman, J., Ling, C., Sandor, M., & Fabry, Z. (2004). Dendritic cells in the initiation of 
immune responses against central nervous system-derived antigens. Immunology 
Letters, 92(1), 107?115. 
Kleihues, P., & Sobin, L. H. (2000). World Health Organization classification of tumors. 
Cancer, 88(12), 2887?2887. 
Lauterbach, H., Zuniga, E. I., Truong, P., Oldstone, M. B., & McGavern, D. B. (2006). 
Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen 
presentation during clearance of a persistent viral infection. The Journal of 
Experimental Medicine, 203(8), 1963?1975. 
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. 
???? ??????? ?????????????????????????????????????????????????????????????????
Induces Systemic and Intracranial T-cell Responses Modulated by the Local 
Central Nervous System Tumor Microenvironment. Clinical Cancer Research, 
11(15), 5515?5525. https://doi.org/10.1158/1078-0432.CCR-05-0464 
Lippitz, B.E. (2013). Cytokine patterns in patients with cancer: a systematic review. 
Lancet Oncol. 14, e218?e228. 
Liu, G., Ying, H., Zeng, G., Wheeler, C. J., Black, K. L., & Yu, J. S. (2004). HER-2, 
gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by 





Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., ... & 
Kleihues, P. (2007). The 2007 WHO classification of tumours of the central 
nervous system. Acta neuropathologica, 114(2), 97-109. 
Lu, J., Gaudreault, J., Novotny, W., Lum, B., & Bruno, R. (2004). A population 
pharmacokinetic model for bevacizumab. Clinical Pharmacology & Therapeutics, 
75(2), P91?P91. 
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990). Response 
criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical 
Oncology, 8(7), 1277?1280. 
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., ... & 
Raulet, D. H. (2014). Recognition of tumors by the innate immune system and 
natural killer cells. Advances in immunology, 122, 91. 
Masson, F., Calzascia, T., Di Berardino-Besson, W., de Tribolet, N., Dietrich, P.-Y., & 
Walker, P. R. (2007). Brain microenvironment promotes the final functional 
maturation of tumor-specific effector CD8+ T cells. The Journal of Immunology, 
179(2), 845?853. 
Maxwell, M., Naber, S. P., Wolfe, H. J., Hedley-Whyte, E. T., Galanopoulos, T., Neville-
Golden, J., & Antoniades, H. N. (1991). Expression of angiogenic growth factor 
genes in primary human astrocytomas may contribute to their growth and 
progression. Cancer Research, 51(4), 1345?1351. 
Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy comes of age. 




Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981). Reporting results of 
cancer treatment. Cancer, 47(1), 207?214. https://doi.org/10.1002/1097-
0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 
Mischo Kursar, Kerstin Bonhagen, Joachim Fensterle, Köhler, A., Robert Hurwitz, 
???????????????? ? ?????????????????????gulatory CD4+CD25+ T cells restrict 
memory CD8+ T cell responses. The Journal of Experimental Medicine, 196(12), 
1585?1592. 
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. 
???? ????????????????????????????????????????nd CCL3 improve dendritic cell 
vaccines in mice and glioblastoma patients. Nature, 519(7543), 366?369L. 
Molecular and Functional Analysis of Tyrosinase-?????????????????????????????
Immunotherapy. (n.d.). Retrieved October 14, 2016, from 
http://journals.lww.com/immunotherapy-
journal/Fulltext/2003/07000/Molecular_and_Functional_Analysis_of.2.aspx 
??????? ?????????????? ??????????????????????????????????????????????????????? ?????? ?
Schneider, C. (2006). MAGE-A tumor antigens target p53 transactivation 
function through histone deacetylase recruitment and confer resistance to 
chemotherapeutic agents. Proceedings of the National Academy of Sciences, 
103(30), 11160?11165. https://doi.org/10.1073/pnas.0510834103 
Motz, G. T., & Coukos, G. (2013). Deciphering and Reversing Tumor Immune 





Mrass, P., & Weninger, W. (2006). Immune cell migration as a means to control immune 
privilege: lessons from the CNS and tumors. Immunological Reviews, 213(1), 
195?212. 
Nduom, E. K., Bouras, A., Kaluzova, M., & Hadjipanayis, C. G. (2012). Nanotechnology 
applications for glioblastoma. Neurosurgery Clinics of North America, 23(3), 
439-449. 
Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. 
(1997). Temozolomide: a review of its discovery, chemical properties, pre-clinical 
development and clinical trials. Cancer Treatment Reviews, 23(1), 35?61. 
Nguyen, D. X., & Massagué, J. (2007). Genetic determinants of cancer metastasis. 
Nature Reviews Genetics, 8(5), 341?352. 
Ofek, P., Fischer, W., Calderón, M., Haag, R., & Satchi-Fainaro, R. (2010). In vivo 
delivery of small interfering RNA to tumors and their vasculature by novel 
dendritic nanocarriers. The FASEB Journal, 24(9), 3122-3134. 
Okano, F., Storkus, W. J., Chambers, W. H., Pollack, I. F., & Okada, H. (2002). 
Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte 
Epitope in a Human Glioma-???????????????????????????????????????????????
Chain. Clinical Cancer Research, 8(9), 2851?2855. 
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & 
Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative 





Pallini, R., Ricci-????????????? ???????????? ??????????????????????? ?????????????? ?
Larocca, L. M. (2011). Expression of the stem cell marker CD133 in recurrent 
glioblastoma and its value for prognosis. Cancer, 117(1), 162?174. 
https://doi.org/10.1002/cncr.25581 
Patel, M. A., Kim, J. E., Ruzevick, J., Li, G., & Lim, M. (2014). The future of 
glioblastoma therapy: synergism of standard of care and immunotherapy. 
Cancers, 6(4), 1953-1985. 
Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., N????? ?????? ?
Yu, J. S. (2012). Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for 
patients with newly diagnosed glioblastoma. Cancer Immunology, 
Immunotherapy, 62(1), 125?135. https://doi.org/10.1007/s00262-012-1319-0 
Prins, R. M., Wang, X?????????????????????????????????????????????????? ?????????? ??
(2013). Comparison of glioma-associated antigen peptide-loaded versus 
autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma 
patients. Journal of Immunotherapy (Hagersto???? ??????????, 36(2), 152?157. 
https://doi.org/10.1097/CJI.0b013e3182811ae4 
Rascher, G., Fischmann, A., Kröger, S., Duffner, F., Grote, E.-H., & Wolburg, H. (2002). 
Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: 
spatial segregation of tenascin and agrin. Acta Neuropathologica, 104(1), 85?91. 
Sabado, R. L., & Bhardwaj, N. (2013). Dendritic cell immunotherapy. Annals of the New 






Saikali, S., Avril, T., Collet, B., Hamlat, A., Bansard, J.-???????????????? ??????????????
(2006). Expression of nine tumour antigens in a series of human glioblastoma 
multiforme: interest of EGFRvIII, IL-????????????????????-2 for 
immunotherapy. Journal of Neuro-Oncology, 81(2), 139?148. 
https://doi.org/10.1007/s11060-006-9220-3 
Sakaguchi, S. (2004). Naturally arising CD4+ regulatory T cells for immunologic self-
tolerance and negative control of immune responses. Annu. Rev. Immunol., 22, 
531?562. 
????????????????????????????????????????????????????????????????????????????? ??? ?
Takahashi, T. (2001). Immunologic tolerance maintained by CD25+ CD4+ 
regulatory T cells: their common role in controlling autoimmunity, tumor 
immunity, and transplantation tolerance. Immunological Reviews, 182(1), 18. 
Sedighim, S., Hsu, M., Wang, T., Everson, R. G., Tucker, A., Ant?????????????? ???????????
(2016). Abstract 767: TCR sequencing can identify and track tumor-specific T 
cell populations and is a predictive biomarker of response to DC vaccination in 
glioblastoma patients. Cancer Research, 76(14 Supplement), 767?767. 
https://doi.org/10.1158/1538-7445.AM2016-767 
??????????????????????????????????????????????????????????????? ???????????????????? ?
Wen, P. Y. (2006). Comparison of linear and volumetric criteria in assessing 
tumor response in adult high-grade gliomas. Neuro-Oncology, 8(1), 38?46. 
https://doi.org/10.1215/S1522851705000529 
States, C. B. T. R. of the U., & others. (2010). CBTRUS statistical report: primary brain 




Stefanik, D. F., Fellows, W. K., Rizkalla, L. R., Rizkalla, W. M., Stefanik, P. P., Deleo, 
A. B., & Welch, W. C. (2001). Monoclonal antibodies to vascular endothelial 
growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 
glioma in a mouse xenograft. Journal of Neuro-Oncology, 55(2), 91?100. 
Stiles, C. D., & Rowitch, D. H. (2008). Glioma stem cells: a midterm exam. Neuron, 
58(6), 832?846. 
Stupp, R. (2006). European Organisation for Research and Treatment of Cancer Brain 
Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical 
Trials Group, Changing paradigms-An update on the multidisciplinary 
management of malignant glioma. The Oncologist, 11, 165?180. 
Stupp, R., Dietrich, P.-???????????????????????????????? ????????????? ??????????? ?????????
(2002). Promising survival for patients with newly diagnosed glioblastoma 
multiforme treated with concomitant radiation plus temozolomide followed by 
adjuvant temozolomide. Journal of Clinical Oncology, 20(5), 1375?1382. 
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001). Current and future 
developments in the use of temozolomide for the treatment of brain tumours. The 
Lancet Oncology, 2(9), 552?560. https://doi.org/10.1016/S1470-2045(01)00489-2 
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. 
???? ???????????????????????????????????????????????????????????????????????
temozolomide versus radiotherapy alone on survival in glioblastoma in a 
randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The 




Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., 
??????????????????????????????????????????????????????????????????????????????
glioblastoma. New England Journal of Medicine, 352(10), 987?996. 
?????????????????????????????????????????????????????? ?????????????????????????? ?
Chapman, P. B. (2004). Selective CD4+ Lymphopenia in Melanoma Patients 
Treated With Temozolomide: A Toxicity With Therapeutic Implications. Journal 
of Clinical Oncology, 22(4), 610?616. https://doi.org/10.1200/JCO.2004.07.060 
Takahashi, J. A., Fukumoto, M., Igarashi, K., Oda, Y., Kikuchi, H., & Hatanaka, M. 
(1992). Correlation of basic fibroblast growth factor expression levels with the 
degree of malignancy and vascularity in human gliomas. Journal of 
Neurosurgery, 76(5), 792?798. 
Tambuyzer, B. R., Ponsaerts, P., & Nouwen, E. J. (2009). Microglia: gatekeepers of 
central nervous system immunology. Journal of Leukocyte Biology, 85(3), 352?
370. 
Thomas, A. A., Ernstoff, M. S., & Fadul, C. E. (2012). Immunotherapy for the treatment 
of glioblastoma. Cancer Journal (Sudbury, Mass.), 18(1), 59. 
???????????? ????????????????????????????????????????????????????????????????????? ?
others. (2003). Marked inactivation of O6-alkylguanine-DNA alkyltransferase 
activity with protracted temozolomide schedules. British Journal of Cancer, 
88(7), 1004?1011. 
Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2012). Targeting the PD-1/B7- H1(PD-




Ung, N., & Yang, I. (2015). Nanotechnology to augment immunotherapy for the 
treatment of glioblastoma multiforme. Journal of neuro-oncology, 123(3), 473-
481. 
Vauleon, E., Avril, T., Collet, B., Mosser, J., & Quillien, V. (2010). Overview of cellular 
immunotherapy for patients with glioblastoma. Clinical and Developmental 
Immunology, 2010. Retrieved from 
http://downloads.hindawi.com/journals/cdi/2010/689171.pdf 
Walker, D. G., Laherty, R., Tomlinson, F. H., Chuah, T., & Schmidt, C. (2008). Results 
of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential 
interaction with adjuvant chemotherapy. Journal of Clinical Neuroscience, 15(2), 
114?121. https://doi.org/10.1016/j.jocn.2007.08.007 
????????????????????????????????????????????????????? ?????????????????????????????on of 
mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to 
and killing of tumor cells. Haematologica, 98(9), 1458?1466. 
https://doi.org/10.3324/haematol.2012.071340 
Wesolowski, J. R., Rajdev, P., & Mukherji, S. K. (2010). Temozolomide (Temodar). 
American Journal of Neuroradiology, 31(8), 1383?1384. 
Wheeler, C. J., Black, K. L., Liu, G., Mazer, M., Zhang, X. X., Pepkowitz, S., ... & John, 
S. Y. (2008). Vaccination elicits correlated immune and clinical responses in 
glioblastoma multiforme patients. Cancer research, 68(14), 5955-5964. 
Wilson, E. H., Weninger, W., & Hunter, C. A. (2010). Trafficking of immune cells in the 




Xie, T., Nguyen, T., Hupe, M., & Wei, M. L. (2009). Multidrug Resistance Decreases 
with Mutations of Melanosomal Regulatory Genes. Cancer Research, 69(3), 992?
999. https://doi.org/10.1158/0008-5472.CAN-08-0506 
??????????????????????????????? ??? ????????????????? ??????????????????????????-Specific 
T-Cell Response from Dendritic Cell Vaccination Using Cancer Stem-Like Cell-
Associated Antigens. STEM CELLS, 27(8), 1734?1740. 
https://doi.org/10.1002/stem.102 
Yamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., ... & 
Tanaka, R. (2005). Clinical evaluation of dendritic cell vaccination for patients 
with recurrent glioma: results of a clinical phase I/II trial. Clinical Cancer 
Research, 11(11), 4160-4167. 
Yong-Jun Liu. (n.d.). Dendritic Cell Subsets and Lineages, and Their Functions in Innate 
and Adaptive Immunity. Cell., 106(3), 259?262. https://doi.org/10.1016/S0092-
8674(01)00456-1 
Yung, W. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., 
?????????????????? ????????????????????????????????????????e in patients with 
anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of 
Clinical Oncology, 17(9), 2762?2762. 
?????? ??????????????????????????????????????????????????????????????????????? ?????? ?
others. (2000). A phase II study of temozolomide vs. procarbazine in patients with 






M. R. (2007). Antigenic Profiling of Glioma Cells to Generate Allogeneic 
Vaccines or Dendritic Cell?Based Therapeutics. Clinical Cancer Research, 13(2), 
566?575. https://doi.org/10.1158/1078-0432.CCR-06-1576 
??????????????????????????????????????????????????? ????????????????????????? ?Jadus, M. R. 
(2008). Tumor antigen precursor protein profiles of adult and pediatric brain 
tumors identify potential targets for immunotherapy. Journal of Neuro-Oncology, 
88(1), 65?76. https://doi.org/10.1007/s11060-008-9534-4 
 
